CERO Therapeutics Holdings, Inc. announced on April 9, 2025, its first clinical trial site for the Phase 1 clinical trial of CER-1236. The University of Texas MD Anderson Cancer Center will lead the trial, focusing on patients with acute myeloid leukemia (AML).
Patient enrollment for the trial is currently underway, with the first patient expected to be dosed during the first half of 2025. The study will be led by Abhishek Maiti, M.D., assistant professor of Leukemia at MD Anderson Cancer Center.
The first-in-human, multi-center, open-label, Phase 1/1b study is designed to evaluate the safety and preliminary efficacy of CER-1236 in patients with relapsed/refractory AML, measurable residual disease, or TP53 gene mutation. CEO Chris Ehrlich noted that conducting the trial at a renowned cancer center validates the scientific work performed to date with CER-1236.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.